Pluvicto, Novartis’ blockbuster radiopharmaceutical for prostate cancer, has been greenlighted by the FDA for use earlier in ...
Top FDA official Peter Marks was forced to resign as the director of the Center for Biologics Evaluation and Research.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback